Akebia Therapeutic’s Vafseo® (vadadustat) Granted Additional Patent
Key Highlights
- ➤Patent No. 12,797,375 extends Vafseo protection through January 18, 2043
- ➤New patent covers modulation of drug-drug interactions during vadadustat treatment
- ➤Fourteen other vadadustat patents have Orange Book expirations from 2027 to 2036
- ➤Vafseo has been available in the U.S. since January 2025
Expert Statements
John P. Butler, Chief Executive Officer of Akebia Therapeutics
“We are pleased to continue to build the vadadustat patent portfolio with this new patent that has a term to January 2043, and which we believe enhances the long-term value of Vafseo”
John P. Butler, Chief Executive Officer of Akebia Therapeutics
“We believe Vafseo can become the standard of care for the treatment of anemia due to chronic kidney disease, supported by compelling clinical outcomes and strong intellectual property protection to position Vafseo competitively in the market for years to come.”
New patent with term until 2043 further strengthens patent portfolio
WALTHAM, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that a new patent has been granted for Vafseo® (vadadustat), strengthening Akebia’s vadadustat intellectual property portfolio. The patent, issued by the United States Patent and Trademark Office (USPTO) on November 17, 2026, as U.S. Patent No. 12,797,375 is eligible for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) and has a term to January 18, 2043.
Get started
Create a free account to read the full story.
